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Background: The personality trait neuroticism has been implicated in a poor response
to stress, may relate to increased concentrations of cytokines and the development
of depression. Inflammatory mechanisms may also be associated with the onset,
severity and symptoms of depression. Both are related to poor antidepressant treatment
outcome. Therefore, mediators of inflammation may bridge the relationship between
neuroticism and depression.
Methods: To disentangle these interrelationships, the associations between neuroticism
(according to NEO-PIR-N), depressive symptoms (BDI-II scores) and serum levels of
hsCRP, TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, GM-CSF were investigated
in a group of 212 participants, consisting of 37 depressed and 175 non-depressed
subjects. A mediation model was used to investigate whether the impact of neuroticism
on depressive symptoms may be mediated by cytokines.
Results: Regression analyses revealed that IFN-γ, IL-5, and IL-12-levels, but none of
the anti-inflammatory cytokines, were associated with the overall neuroticism score and
several of the cytokines were related to the different facets of neuroticism. TNF-α, IFN-γ,
IL-5, IL-12, and IL-13 were further related to the severity of depressive symptoms, as well
as the somatic-affective and the cognitive dimensions of depression. Pro-inflammatory
IFN-γ, IL-5 and IL-12 were identified as mediators of the positive prediction of depression
severity by the degree of neuroticism.
Conclusions: The current findings demonstrate that conditions related to long-term
stress, such as depression and high neuroticism, are related to an up-regulation of
inflammatory agents. Neuroticism may increase stress perception and, thus, increase
the production of pro-inflammatory messenger molecules which are involved in the
development of depression. This evidence may contribute to future anti-inflammatory
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interventions, particularly in subjects with high neuroticism who are at risk for developing
depression. Furthermore, depressed patients with high neuroticism and cytokine levels
may require early escalations in the intensity of treatment, along with additional
therapeutic elements to increase the rate of treatment success.
Keywords: neuroticism, depression, chronic stress, cytokines, TNF-α, mediation analyses
INTRODUCTION
Neuroticism, as one of the Big Five higher-order
personality traits, represents the tendency to experience negative
emotions, such as anxiety and anger, and to have an increased
perception of stress, as well as the inability to relieve the self from
and to cope with stress (1). Acute and chronic stress have been
shown to significantly influence cytokine production in human
and animal studies (2, 3). In accord, higher neuroticism as well
as stress-related disorders, such as post-traumatic stress disorder
(PTSD), have been found to be associated with higher levels
of pro-inflammatory agents (4, 5). However, investigations on
neuroticism have been limited to a few inflammatory parameters:
for example, C-reactive protein (CRP) or interleukin (IL)-6, for
which the relationship with neuroticism could not be confirmed
(6). Importantly, neuroticism is considered a risk factor for the
development and onset of major depression and certain subtypes
of depression (7–9). However, the biological mechanisms for this
relationship are not yet well understood.
Alongside neuroticism, a body of evidence supports the
involvement of low-grade inflammation in the pathogenesis of
depressive disorders (10). Accordingly, cross-sectional studies
have demonstrated an association between pro-inflammatory
markers and the presence, course and treatment outcome
of major depression (11–14). Inconsistent results have been
observed in the relationship between pro-inflammatory
cytokines and the severity of depressive symptoms, as
measured in cohorts of patients with major depression or
physical illnesses concomitant with depressive syndromes,
and in population-based studies (15–22). Additionally,
anti-inflammatory cytokines have gained little attention in
these investigations (15, 23). The relationship between the
symptoms and severity of depression and cytokine regulation
should be interpreted with caution given that the majority
of investigations were limited to a few parameters, in
particular CRP and IL-6, and relevant confounders, such as
the distribution of sexes, have not always been taken into account
sufficiently.
Given that only a small number of mediators of inflammation
have yet been investigated with regards to neuroticism, results on
inflammation and depressive symptomatology are inconclusive
and the biological pathways for the relationship between
neuroticism and depression are unidentified. Therefore, the
aim of this study was firstly to investigate the hypothesis
that pro- and anti-inflammatory markers are associated with
the severity of depressive symptoms and the personality
trait neuroticism. Secondly, we aimed to explore if cytokines
mediate the relationship between depressive symptoms and
neuroticism.
METHODS
Participants
The presented data were collected as part of the “OBDEP”
research project (Obesity and Depression: pathogenetic role
of sleep and wakefulness regulation, motor activity level and
neurochemical aspects). Three-hundred and four participants
were initially recruited from the outpatient clinic of the
Integrated Research and Treatment Center (IFB) for Adiposity
Diseases Leipzig, from the Department of Psychiatry and
Psychotherapy at the University Hospital Leipzig and via
advertisements (intranet, internet, local newspapers). Evaluation
of inclusion and exclusion criteria for the study was performed
in two stages, as previously reported (24). First, potential
participants took part in a telephone screening interview,
which involved collecting socio-demographic data, assessing the
presence of physical illnesses and completing a checklist of
the Structured Clinical Interview for DSM-IV [SCID-I; (25)].
Following this, potentially eligible participants were invited to
the study center, where exclusion criteria were assessed in
more detail. In cases of positive SCID-screening or known
diagnosis of depression, the SCID-I was performed in full.
Exclusion criteria were DSM-IV Axis 1 disorders for the non-
depressed participants and DSM-IV Axis 1 disorders other
than a major depression for the depressed subjects. For
all subjects, further exclusion criteria were acute or chronic
infections (according to clinical investigation and/or CRP ≥ 10
mg/l), current medication treatment with a non-steroidal anti-
inflammatory drug (NSAID), the presence of current and/or
past neurological disorders, and a history of head injury with
loss of consciousness exceeding 1 h. Assessments for current
and past history of health problems and current medication
were performed using standardized questionnaires. Only data
sets of participants who completed both the Beck Depression
Inventory II [BDI-II; (26)] and the Revised NEO Personality
Inventory [NEO-PIR-N; (27)] were included in the statistical
analyses presented herewith, resulting in a total sample of 212
participants, including 175 non-depressed and 37 depressed
subjects. All participants were aged 18–70 years. Written
informed consent was obtained from all participants. The study
was approved by Leipzig University Ethics Committee (#015-10-
18012009).
Assessments
Depressive symptoms were assessed using the Beck Depression
Inventory II [BDI-II; (26)]. Along with a total sum score, sub-
scale scores for a somatic-affective factor and a cognitive factor
were calculated (28). The somatic-affective factor was calculated
by summation of scores on items 4, 11-13, and 15-21 and
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the cognitive factor by summation of scores on items 1-3,
5-9, and 14. To assess neuroticism, the neuroticism domain
(consisting of six dimensions: anxiety, hostility, depression, self-
consciousness, stress vulnerability, impulsiveness) of the Revised
NEO Personality Inventory [NEO-PIR-N; (27)] was used.
Cytokine Measurement
After blood drawing, serum probes were immediately centrifuged
at 3,000 rpm for 10min. The supernatant was aliquoted and
stored in non-absorbing polypropylene tubes of 300 µl. Probes
were shock-frozen in liquid nitrogen and stored in freezers
at −80◦C until required. Cytokines were measured using the
TABLE 1 | Sociodemographic details for the total sample, and for participants
with and without a diagnosis of major depression, separately.
Participants
total
Participants
non-depressed
Participants
depressed
(N = 212) (N = 175) (N = 37)
Sex [male/female] 81/131 62/113 19/18
Age [years] (mean ± SD) 37.14 ± 12.01 36.61 ± 13.04 39.62 ± 12.73
Smoker (yes/no) 48/164 37/138 11/26
BMI [kg/m²] (mean ± SD) 34.71 ± 13.00 35.28 ± 12.25 32.02 ± 10.61
Marital status
married or cohabiting 53 (25.0%) 39 (22.3%) 14 (37.8%)
Divorced 23 (10.8%) 17 (9.7%) 6 (16.2%)
Widowed 3 (1.4%) 2 (1.1%) 1 (2.7%)
Single 131 (61.8%) 115 (65.7%) 16 (43.2%)
NA 1.2% 2 (1.2%) 0
Occupational status
Employed 106 (50.0%) 85 (48.6%) 21 (56.8%)
Unemployed 47 (22.2%) 38 (21.7%) 9 (24.3%)
Retired 12 (5.7%) 8 (4.6%) 4 (10.8%)
Student 40 (18.9%) 37 (21.1%) 3 (8.1%)
Homemaker 4 (1.9%) 4 (2.3%) 0
NA 3 (1.4%) 3 (1.7%) 0
Comorbid Disorders (yes) 87 (41.0%) 73 (41,7%) 14 (37,8%)
None 125 (59.0%) 102 (58.3%) 23 (62.2%)
Arterial hypertension 50 (23.6%) 42 (24.0%) 8 (21.6%)
Hypothyreosis 36 (16.9%) 31 (17.7%) 5 (13.5%)
Diabetes 25 (11.8%) 24 (13.7%) 1 (2.7%)
Obstructive sleep apnea
syndrome
8 (3.8%) 7 (4.0%) 1 (2.7%)
Asthma 7 (3.3%) 6 (4.1%) 1 (2.7%)
Cerebrovascular
disorders/Myocardial
infarction
12 (5.7%) 8 (4.6%) 4 (10.8%)
Medication (yes) 60 (28.3%) 52 (29.7%) 8 (21.6%)
None 152 (71.7%) 123 (70.3%) 29 (78.4%)
ACE-blocker 28 (13.2%) 26 (14.9%) 2 (5.4%)
Beta-blocker 25 (11.8%) 22 (12.6%) 3 (8.1%)
Hypoglycaemics 25 (11.8%) 24 (13.7%) 1 (2.7%)
AT1-blocker 18 (8.5%) 12 (6.9%) 5 (13.5%)
Calcium chanel blocker 9 (4.2%) 7 (5.7%) 2 (5.4%)
Statins 3 (1.4%) 3 (1.7%) 0
Bio-Plex Pro human cytokine Th1/Th2 immunoassay from Bio
Rad, Germany, a 96-well kit that uses coupled magnetic beads
and detection antibodies. This multiplex assay detects IL-2, IL-
4, IL-5, IL-10, IL-12, IL-13, GM-CSF, IFN-γ, and TNF-α. The
intraassay coefficient of variation (CV) for cytokines was between
1.6 and 3.8%. High sensitivity (hs)-CRP was measured using a
turbidimetric assay on an AU 5800 analyzer, Beckman Coulter,
Germany. For hs-CRP intraassay CV was 4.1%.
Statistics
CRP and the nine pro- and anti-inflammatory cytokines were
log-transformed in order to obtain approximately normally
TABLE 2 | Sum total and dimension scores for depression and neuroticism, and
concentrations of markers of inflammation in the total sample, and for participants
with and without a diagnosis of major depression, separately.
Participants
total
Participants
non-
depressed
Participants
depressed
(N = 212) (N = 175) (N = 37)
BDI-II sum score (mean
± SD)
11.01 ± 11.34 7.65 ± 7.81 26.95 ± 11.94
Somatic-affective
dimension (mean ± SD)
6.21 ± 6.37 4.33 ± 4.38 15.63 ± 6.47
Cognitive dimension
(mean ± SD)
4.14 ± 4.89 2.98 ± 3.64 10.33 ± 5.98
NEO-PIR-N sum score
(mean ± SD)
89.15 ± 28.01 83.23 ± 25.59 117.14 ± 21.39
Anxiety dimension (mean
± SD)
15.23 ± 6.04 14.03 ± 5.51 20.89 ± 5.17
Hostility dimension (mean
± SD)
15.15 ± 5.49 14.30 ± 5.19 19.16 ± 5.10
Depression dimension
(mean ± SD)
14.49 ± 7.55 12.76 ± 6.70 22.65 ± 5.60
Self-consciousness
dimension (mean ± SD)
16.56 ± 5.57 15.66 ± 5.35 20.81 ± 4.59
Impulsiveness dimension
(mean ± SD)
14.72 ± 4.11 14.73 ± 4.14 14.68 ± 4.02
Stress vulnerability
dimension (mean ± SD)
13.00 ± 6.05 11.75 ± 5.28 18.95 ± 5.95
CRP levels [mg/dl] (mean
± SD)
0.68 ± 0.78 0.69 ± 0.76 0.65 ± 0.85
TNF-α levels [pg/ml]
(mean ± SD)
30.37 ± 18.02 28.69 ± 16.56 38.29 ± 22.34
IFN-γ levels [pg/ml]
(mean ± SD)
149.67 ± 113.18 119.58 ± 67.38 292.97 ± 167.10
IL-2 levels [pg/ml] (mean
± SD)
6.46 ± 8.13 6.46 ± 8.42 6.46 ± 6.71
IL-4 levels [pg/ml] (mean
± SD)
3.78 ± 2.23 3.80 ± 2.30 3.66 ± 1.90
IL-5 levels [pg/ml] (mean
± SD)
3.14 ± 2.45 2.75 ± 1.98 4.99 ± 3.45
IL-10 levels [pg/ml]
(mean ± SD)
6.54 ± 26.75 6.90 ± 29.31 4.83 ± 6.25
IL-12 levels [pg/ml]
(mean ± SD)
14.35 ± 18.79 11.41 ± 17.01 28.26 ± 20.73
IL-13 levels [pg/ml]
(mean ± SD)
6.20 ± 6.46 5.76 ± 6.46 8.26 ± 6.13
GM-CSF levels [pg/ml]
(mean ± SD)
35.01 ± 20.08 33.73 ± 18.53 42.98 ± 25.01
Time of blood drawings
(mean ± SD)
11 : 51 ± 2 : 28 11 :56 ± 2 : 32 11 : 26 ± 2 :10
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distributed variables. We investigated the association between
depressive symptoms and neuroticism with the log-transformed
serum concentrations of CRP and the cytokines by linear
regression analyses.
Multiple regression analyses were performed to determine
the relationship between the dependent variable (i.e., depressive
symptoms according to BDI-scores) and each of the log-
transformed CRP and cytokine values. Regression analyses were
controlled for confounding variables known to impact cytokine
levels: age, sex, smoking status, BMI and time of blood drawing.
Sum values of the physical illnesses and medication listed
in Table 1 were further included as control variables ranging
from 0 (“none”) to the maximum of 4. Levels of significance
were adjusted for multiple testing using the False Discovery
Rate [FDR; according to (29)] for BDI-II, NEO-PIR-N and
the respective cytokines separately. For all other analyses, the
level of significance was set at p < 0.05. Mediation analyses
were performed for those cytokines significantly associated
with sum scores of both BDI-II and NEO-PIR-N. For the
mediation analyses, residuals were calculated for logTNF-α,
logIFN-γ, logIL-5, logIL-12, logIL-13, BDI-II sum scores and
NEO-PIR-N sum scores through listwise-regression analyses in
order to exclude significant confounders. Covariates included
into the analyses were: “age,” “sex,” “BMI,” “smoking status,”
“time of blood sampling,” “sum of physical illnesses,” and “sum
of medication.” After excluding multicollinearity between the
parameters, mediation analyses were performed with the freely
available SPSS macro “sobel” (http://www.processmacro.org/
download.html), which includes bootstrapping and Sobel test
(30). All further analyses were performed with SPSS Version 24
(IBM Corporation; Armonk, NY, USA).
RESULTS
Two hundred twelve participants, consisting of 37 depressed
and 175 non-depressed subjects, were included in the final
analyses. Demographic data, including medication status and the
presence of physical illnesses, are presented in Table 1. Serum
concentrations of CRP and cytokines, depression symptoms and
neuroticism scores are shown in Table 2.
CRP, Cytokines and Depression Symptoms
Linear regression analyses showed a significant increase in the
severity of depressive symptoms associated with higher logTNF-
α, logIFN-γ, logIL-5, logIL-12, and logIL13 (Table 3). The BDI-
II sum score increased by a coefficient of up to 15.5 for each
standard deviation of logIFN-γ, followed by 9.2 for each standard
deviation of logTNF-α, by a coefficient of 9.2 for logIL-5, 6.7 for
logIL-12 and 6.4 for logIL-13. Scores on the somatic-affective and
cognitive dimensions of the BDI-II were significantly associated
with logTNF-α, logIFN-γ, logIL-5, logIL-12, logIL13 and logGM-
CSF. No significant association between the sum scores, the
dimensions of depression and the cytokine levels were observed
for logIL-2, logIL-4 or logIL-10 and also logCRP.
CRP, Cytokines and Neuroticism
Linear regression analyses between the pro-and anti-
inflammatory markers, the six different dimensions of
neuroticism and the sum score of neuroticism showed that
a significant increase in the magnitude of neuroticism (NEO
PI-R-N sum score) was dependent on higher logIFN-γ, logIL-5
and logIL-12 after correcting for multiple testing (Table 4). The
increase in the anxiety dimension was predicted by logIFN-γ
and logIL-12 levels. The depression dimension was found to
significantly depend on logIFN-γ, logIL-5, and logIL-12. The
self-consciousness dimension depended significantly on all
parameters except logCRP and logIL4. The stress vulnerability
dimension depended on logTNF-α, logIFN-γ, logIL-5, logIL-
10, logIL-12, and logIL-13. The hostility dimension and the
impulsiveness dimension were not associated with any of the
cytokines.
Relationship Between Neuroticism,
Depressive Symptoms and Inflammatory
Markers
In a first step, the residuals of the BDI-II scores were predicted by
the residuals of the NEO-scores. In a second step, the residuals of
TABLE 3 | Regression analyses between inflammatory agents and dimensions of depression.
BDI-II sum score Somatic-affective dimension Cognitive dimension
logCRP 6.109 (−6.737 to 18.955) = 0.350 3.574 (−3.663 to 10.811) = 0.331 1.788 (−3.795 to 7.370) = 0.528
logTNF-α 9.212 (3.017 to 15.408) =0.004* 6.011 (2.528 to 9.494), <0.001* 3.849 (1.116 to 6.582) = 0.006*
log IFN-γ 15.517 (10.463 to 20.571), <0.001* 8.723 (5.854 to 11.593), <0.001* 5.939 (3.697 to 8.180), <0.001*
log IL-2 1.974 (−1.107 to 5.056) = 0.208 1.160 (−0.576–2.897) = 0.189 0.956 (−0.383 to 2.294) = 0.161
log IL-4 3.219 (−4.954 to 11.392) = 0.438 2.216 (−2.425 to 6.858) = 0.348 1.801 (−1.753 to 5.354) = 0.319
log IL-5 9.248 (4.664 to 13.832), <0.001* 5.904 (3.341 to 8.468), <0.001* 3.244 (1.228 to 5.260) = 0.002*
log IL-10 3.437 (−0.445 to 7.318) = 0.082 1.998 (−0.193 to 4.190) = 0.074 1.387 (−0.300 to 3.074) = 0.107
log IL-12 6.743 (3.647 to 9.839), <0.001* 3.872 (2.118 to 5.626), <0.001* 3.108 (1.749 to 4.466), <0.001*
log IL-13 6.370 (1.900 to 10.840) =0.005* 3.904 (1.388 to 6.420) = 0.003* 2.860 (0.897 to 4.823) = 0.005*
logGM-
CSF
5.531 (0.119 to 10.944) = 0.045 3.198 (0.150 to 6.246) = 0.040 2.839 (0.491 to 5.187) = 0.018*
Coefficient (95%-CI), p-value. Significant correlations are highlighted in bold font. Significance after correction for multiple comparisons is labeled with an asterisk.
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the cytokine levels (logTNF-α, logIFN-γ, logIL-5, logIL-12, logIL-
13) were predicted by the residuals of the NEO-scores. In a third
step, the residuals of the BDI-II-scores were predicted by the
residuals of the cytokine levels and the NEO-scores. The results
of the regression analyses are presented in Table 5
The bootstrapping analysis withm= 5,000 estimates revealed
a significant indirect effect of the residuals of the NEO-scores on
the residuals of the BDI-scores through the residuals of logIFN-
γ (95% CI 0.0097, 0.0462), logIL-5 (95% CI 0.0027, 0.0230) and
logIL-12 (95% CI 0.0013, 0.0291) -residuals. As an example, the
standardized coefficients of regression for logIFN-γ are depicted
in Figure 1. The Sobel-Z-test revealed a significant effect for
the residuals through logIFN-γ (Z = 2.88, p = 0.004) that was
trending for logIL-5 (Z = 1.89, p = 0.059) and IL-12 (Z = 1.91,
p= 0.056).
DISCUSSION
The current findings on the relationship between both pro- and
anti-inflammatory markers and characteristics of depression and
neuroticism confirmed our hypothesis of a positive association
between inflammatory agents and the degree of depression
and neuroticism. The results further revealed that markers of
inflammation may be significant mediators for the positive
relationship between neuroticism and depressive symptoms.
After correcting for multiple testing and controlling for
potential confounding variables, the analyses revealed that
depressive symptoms were association with the cytokines TNF-α,
IFN-γ, IL-5, IL-12, and IL-13. These results expand on the range
of cytokines previously investigated. They also add to existing
findings suggesting that a pro-inflammatory state is related to
depressive symptoms in the general population as well as in
TABLE 5 | Mediation analyses Regression analyses between dimensions of
depression, neuroticism and the inflammatory agents.
Criterion Predictor β p
BDI-II NEO 1.60 <0.001
TNF-α NEO 16.42 0.029
IFN-γ NEO 32.11 <0.001
IL-5 NEO 18.38 0.002
IL-12 NEO 15.07 <0.001
IL-13 NEO 4.61 0.016
BDI-II TNF-α 0.009 0.048
NEO 1.566 <0.001
BDI-II IFN-γ 0.017 0.005
NEO 1.448 <0.001
BDI-II IL-5 0.011 0.016
NEO 1.54 <0.001
BDI-II IL-12 0.011 0.026
NEO 1.527 <0.001
BDI-II IL-13 0.0004 0.123
NEO 1.572 <0.001
β, standardized coefficient of regression.
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cohorts of depressed subjects [e.g., (15–17, 31)]. Extending on
previous research that focussed on pro-inflammatory markers,
our analyses could not demonstrate an affection of the degree
of depressive mood and cognition by the anti-inflammatory
mediators IL-4 and IL-10. Though anti-inflammatory cytokines,
have been found to be elevated in major depression and in
response to pro-depressive agents (24, 32, 33), the degree of
depression could previously not be statistically explained by
IL-10 or IL-4 (24, 31). However, the sample sizes here and
in previous studies may, in part, account for the negative
results for which small effect sizes were to be expected (34).
Results of a decreased IL-4-responsiveness of microglia as well
as the inhibition of IL-10-signaling leading to depression-like
behavior in animal models of depression demonstrate the need
for further investigations on the role of anti-inflammatory agents
in depression (35, 36).
The present results do not support the involvement of CRP as
a relevant mediator once relevant covariates were accounted for
(13, 15). In line with this, most of the mechanisms involved in
the inflammation-depression -relationship have been described
for TNF-α and IFN-γ, but not CRP, including the stimulation
of the indolamine-2,3-dioxygenase (IDO) (10), the relationship
with the psychopathology of depression (37–39) and the potential
as an antidepressant drug target (14, 40). As for CRP, the
differences in results between correlation and regression analyses
(41) and the variability in results across other studies, showing
no relationship between cytokines and depressive symptoms
(20, 24), illustrates the need to account for potential confounders.
Studies not including essential confounding parameters, such
as BMI, smoking habits and inflammation-modulating drugs,
should therefore be considered with caution.
Overall neuroticism and also several dimensions of
neuroticism, in particular the self-consciousness and the stress
vulnerability dimensions, were related tomultiple cytokines, such
as IFN-γ and TNF-α; however no such relationship was observed
for the anti-inflammatory IL-4 and IL-10. These associations
highlight the relationship between personality traits leading to
long-term impairments in stress response and the regulation
of mediators of inflammation. There is little data to which we
can compare our findings; however, for CRP, the absence of
associations are in line with a recent meta-analysis showing CRP
and IL-6 not to be related to neuroticism (6). To our knowledge,
this is the first study in the English language to examine the
relationship between neuroticism and the anti-inflammatory
cytokines IL-4 and IL-10, which warrants replication. For
TNF-α, the findings from the limited number of previous studies
conducted are consistent with ours; for example, in patients
with hepatitis C, TNF-α correlated with scores of neuroticism
after therapy (4). Hypothetically, the finding of up-regulation
of markers of inflammation in neuroticism may explain the
increased incidence of a wide range of physical illnesses in
people vulnerable to neuroticism (42). Also, neuroticism may be
associated with increased cytokine levels due to its relationship
with a higher prevalence of obesity and smoking habits, factors
known to up-regulate pro-inflammatory cytokines (9, 43, 44).
With regards to our findings of a relationship between
neuroticism and depressive symptoms, neuroticism has
FIGURE 1 | Mediation model showing the impact of IFN-γ on the association
between neuroticism and depression. Annotations: β, standardized coefficient
of regression, **p < 0.01, ***p < 0.001.
repeatedly been shown to be associated with or to be a risk
factor for the development of depressive disorders (7–9). To the
best of our knowledge, this is the first time that inflammatory
markers have been identified as a relevant mediator of this
association. One possible patho-biological pathway for this link
could be hypothalamic-pituitary-adrenal (HPA) axis activity:
chronic stress induces the upregulation of HPA axis activity as
well as the synthesis of cytokines (45–47). Some cytokines, for
example IFN-γ, in turn stimulate the HPA axis (48). Of note,
HPA axis activity has been found to be altered both in major
depression and neuroticism (45). Other identified links between
neuroticism and depression include a decreased expression
of brain-derived neurotrophic factor (BDNF), as well as the
activity of the anterior cingulate cortex [ACC; (45, 46)], for
which an involvement of cytokines has been described (11, 49).
Regarding the integration of this relationship into antidepressant
treatment strategies, it should be of note that both inflammation
(13, 18) and neuroticism (50, 51) impact on the treatment
outcome of depression. Therefore, depressed patients with high
neuroticism may require more specialized clinical efforts (50).
In addition, the determination of inflammatory mediators as
well as factors associated with increased cytokine levels and
neuroticism, such as obesity and smoking should be taken into
account (9, 19, 43, 44). Psychotherapeutic interventions may
exert anti-depressant effects via modulation of neuroticism (52),
however the question as to whether this is related to observed
reductions of inflammation (53) is yet unknown.
This study needs to be considered in light of several
limitations: The analyses were performed in participants with
a high proportion of obesity which is unlikely to represent the
general population. The sample size of the group of depressed
patients was too small to perform separate analysis in this group
and to rule out type II errors. This may also be the case for the
total number of participants and potential effects with small effect
sizes, like the relationship between depressiveness and serum
levels of IL-4 and IL-10.
Our results show a relationship between depressive symptoms,
neuroticism and cytokine levels, but cannot provide information
on the molecular mechanisms underlying this association. A
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longitudinal design could more clearly demonstrate whether the
personality trait neuroticism contributes to the risk of developing
depression. Further, our analyses highlight the importance of
including several potential covariates into the statistical analyses,
such as BMI,medication status, and concurrent physical illnesses,
due to their potential impact on inflammation. However, a
more distinct impact, e.g., of the dosage of the separate
drugs or the activity and acuity of the diagnoses, remains
unclear.
In conclusion, the current study included 37 depressed
and 175 non-depressed subjects, finding significant associations
between depressive symptoms, the degree and dimensions of
neuroticism and serum levels of pro-inflammatory, but not anti-
inflammatory, cytokines. Further, IFN-γ, IL-5 and IL-12 were
found to be significant mediators of the effect of neuroticism
on depressive symptoms. These findings support the relationship
between depressive psychopathology and pro-inflammatory
conditions. Neuroticism as a long-term psychological stressor
may exert pro-depressive features by facilitating a persistent low-
grade inflammation. Since neuroticism and inflammation are
related to the course of depression, psychotherapeutic emphasis
on neuroticism and pharmacological targeting of inflammation
may contribute to more personalized antidepressant therapeutic
interventions, helping to prevent therapeutic non-response and
the development of a chronic course of illness.
AUTHOR CONTRIBUTIONS
FS and HH designed the study. FS, CS, and HH wrote the
manuscript. LH and DT conducted the chemical analyses. FS
and RM performed the statistical analyses. JM, RM, BD, and
UH revised the manuscript. All authors approved the final
manuscript.
FUNDING
This study was supported by the Integrated Research and
Treatment Centre for Adiposity Diseases (IFB), University
of Leipzig, the Federal Ministry of Education and Research
(BMBF), FKZ: 01EO1001, and the Claussen-Simon-Foundation.
We acknowledge support from the German Research Foundation
(DFG) and Universität Leipzig within the program of Open
Access Publishing. The funding sources had no role in the design
and conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of
the manuscript.
REFERENCES
1. Abbas IS. The role of neuroticism in the maintenance of chronic baseline
stress perception and negative affect. Span J Psychol. (2016) 19:E9.
doi: 10.1017/sjp.2016.7
2. Wirtz PH, von Känel R. Psychological stress, inflammation,
and coronary heart disease. Curr Cardiol Rep. (2017) 19:111.
doi: 10.1007/s11886-017-0919-x
3. Himmerich H, Fischer J, Bauer K, Kirkby KC, Sack U, Krügel U. Stress-
induced cytokine changes in rats. Eur Cytokine Netw. (2013) 24:97–103.
doi: 10.1684/ecn.2013.0338
4. Pawlowski T, Radkowski M, Małyszczak K, Inglot M, Zalewska
M, Jablonska J, et al. Depression and neuroticism in patients with
chronic hepatitis C: correlation with peripheral blood mononuclear
cells activation. J Clin Virol. (2014) 60:105–11. doi: 10.1016/j.jcv.2014.
03.004
5. Hussein S, Dalton B, Willmund GD, Ibrahim MAA, Himmerich H. A
systematic review of tumor necrosis factor-α in post-traumatic stress disorder:
evidence from human and animal studies. Psychiatr Danub. (2017) 29:407–20.
doi: 10.24869/psyd.2017.407
6. Luchetti M, Barkley JM, Stephan Y, Terracciano A, Sutin AR. Five-
factor model personality traits and inflammatory markers: new data
and a meta-analysis. Psychoneuroendocrinology (2014) 50:181–93.
doi: 10.1016/j.psyneuen.2014.08.014
7. Rudaz DA, Vandeleur CL, Gebreab SZ, Gholam-Rezaee M, Strippoli MF,
Lasserre AM, et al. Partially distinct combinations of psychological, metabolic
and inflammatory risk factors are prospectively associated with the onset of
the subtypes of major depressive disorder in midlife. J Affect Disord. (2017)
222:195–203. doi: 10.1016/j.jad.2017.07.016
8. Jeronimus BF, Kotov R, Riese H, Ormel J. Neuroticism’s prospective
association with mental disorders halves after adjustment for baseline
symptoms and psychiatric history, but the adjusted association hardly
decays with time: a meta-analysis on 59 longitudinal/prospective
studies with 443 313 participants. Psychol Med. (2016) 46:2883–906.
doi: 10.1017/S0033291716001653
9. Gale CR, Hagenaars SP, Davies G, Hill WD, Liewald DC, Cullen B, et al.
Pleiotropy between neuroticism and physical andmental health: findings from
108 038 men and women in UK Biobank. Transl Psychiatry (2016) 6:e791.
doi: 10.1038/tp.2016.56
10. Lichtblau N, Schmidt FM, Schumann R, Kirkby KC, Himmerich H. Cytokines
as biomarkers in depressive disorder: current standing and prospects. Int Rev
Psychiatry (2013) 25:592–603. doi: 10.3109/09540261.2013.813442
11. Schmidt FM, Kirkby KC, Lichtblau N. Inflammation and immune regulation
as potential drug targets in antidepressant treatment. Curr Neuropharmacol.
(2016) 14:674–87. doi: 10.2174/1570159X14666160115130414
12. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative
meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-
reactive protein in patients with major depressive disorder. Brain Behav
Immun. (2015) 49:206–15. doi: 10.1016/j.bbi.2015.06.001
13. Uher R, Tansey KE, Dew T,MaierW,Mors O, Hauser J, et al. An inflammatory
biomarker as a differential predictor of outcome of depression treatment
with escitalopram and nortriptyline. Am J Psychiatry (2014) 171:1278–86.
doi: 10.1176/appi.ajp.2014.14010094
14. Schmidt FM, Kirkby KC, Himmerich H. The TNF-alpha inhibitor etanercept
as monotherapy in treatment-resistant depression - report of two cases.
Psychiatr Danub. (2014) 26:288–90.
15. Köhler-Forsberg O, Buttenschøn HN, Tansey KE, Maier W, Hauser
J, Dernovsek MZ, et al. Association between C-reactive protein
(CRP) with depression symptom severity and specific depressive
symptoms in major depression. Brain Behav Immun. (2017) 62:344–50.
doi: 10.1016/j.bbi.2017.02.020
16. Jokela M, Virtanen M, Batty GD, Kivimäki M. Inflammation and
Specific Symptoms of Depression. JAMA Psychiatry (2016) 73:87–8.
doi:10.1001/jamapsychiatry.2015.1977
17. White J, Kivimäki M, Jokela M, Batty GD. Association of inflammation with
specific symptoms of depression in a general population of older people: the
english Longitudinal study of ageing. Brain Behav Immun. (2017) 61:27–30.
doi: 10.1016/j.bbi.2016.08.012
18. Schmidt FM, Schröder T, Kirkby KC, Sander C, Suslow T, Holdt LM, et al. Pro-
and anti-inflammatory cytokines, but not CRP, are inversely correlated with
severity and symptoms of major depression. Psychiatry Res. (2016) 239:85–91.
doi: 10.1016/j.psychres.2016.02.052
19. Schmidt FM, Weschenfelder J, Sander C, Minkwitz J, Thormann J, Chittka
T, et al. Inflammatory cytokines in general and central obesity and
Frontiers in Psychiatry | www.frontiersin.org 7 November 2018 | Volume 9 | Article 609
Schmidt et al. Inflammation, Neuroticism, and Depression
modulating effects of physical activity. PLoS ONE (2015) 10:e0121971.
doi: 10.1371/journal.pone.0121971
20. Dahl J, Ormstad H, Aass HC, Malt UF, Bendz LT, Sandvik L, et al. The
plasma levels of various cytokines are increased during ongoing depression
and are reduced to normal levels after recovery. Psychoneuroendocrinology
(2014) 45:77–86. doi: 10.1016/j.psyneuen.2014.03.019
21. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O’Brien JT. Increase
in Interleukin-1beta in late-life depression. Am J Psychiatry (2005) 162:175–7.
doi: 10.1176/appi.ajp.162.1.175
22. Steptoe A, Kunz-Ebrecht SR, Owen N. Lack of association between
depressive symptoms and markers of immune and vascular inflammation
in middle-aged men and women. Psychol Med. (2003) 33:667–74.
doi: 10.1017/S0033291702007250
23. Ramsey JM, Cooper JD, Bot M, Guest PC, Lamers F, Weickert CS, et al. Sex
differences in serum markers of major depressive disorder in the netherlands
study of depression and anxiety (NESDA). PLoS ONE (2016) 11:e0156624.
doi: 10.1371/journal.pone.0156624
24. Schmidt FM, Lichtblau N, Minkwitz J, Chittka T, Thormann J, Kirkby
KC, et al. Cytokine levels in depressed and non-depressed subjects,
and masking effects of obesity. J Psychiatr Res. (2014) 55:29–34.
doi: 10.1016/j.jpsychires.2014.04.021
25. Wittchen HU, Zaudig M, Fydrich T. SKID Strukturiertes Klinisches Interview
für DSM-IV (Achse I und II) [Structured Clinical Interview for DSM-IV (axis I
and II)]. Göttingen: Hogrefe (1997).
26. Beck AT, Steer RA, Brown GK. BDI–II, Beck Depression Inventory: Manual.
2nd edn. Boston: Harcourt Brace (1996).
27. Costa PT, McCrae RR. NEO PI-R Professional Manual. Odessa, FL:
Psychological Assessment Resources, Inc (1992).
28. Huang C, Chen JH. Meta-Analysis of the factor structures of
the beck depression inventory-II. Assessment (2015) 22:459–72.
doi: 10.1177/1073191114548873
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Stat Soc Series B. (1995) 57:289–300.
30. Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect
effects in simple mediation models. Behav Res Methods Instrum Comput.
(2004) 36:717–31. doi: 10.3758/BF03206553
31. Zou W, Feng R, Yang Y. Changes in the serum levels of inflammatory
cytokines in antidepressant drug-naïve patients with major depression. PLoS
ONE (2018) 13:e0197267. doi: 10.1371/journal.pone.0197267
32. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI,
Pollack MH, et al. A detailed examination of cytokine abnormalities in
major depressive disorder. Eur Neuropsychopharmacol. (2008) 18:230–3.
doi: 10.1016/j.euroneuro.2007.06.004
33. Hernández ME, Mendieta D, Martínez-Fong D, Loría F, Moreno
J, Estrada I, et al. Variations in circulating cytokine levels
during 52 week course of treatment with SSRI for major
depressive disorder. Eur Neuropsychopharmacol. (2008) 18:917–24.
doi: 10.1016/j.euroneuro.2008.08.001
34. Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes
BS, et al. Peripheral cytokine and chemokine alterations in depression:
a meta-analysis of 82 studies. Acta Psychiatr Scand. (2017) 135:373–87.
doi: 10.1111/acps.12698
35. Wachholz S, Knorr A, Mengert L, Plümper J, Sommer R, Juckel G,
et al. Interleukin-4 is a participant in the regulation of depressive-
like behavior. Behav Brain Res. (2017) 326:165–72. doi: 10.1016/j.bbr.
2017.03.02
36. Laumet G, Edralin JD, Chiang AC, Dantzer R, Heijnen CJ, Kavelaars A.
Resolution of inflammation-induced depression requires T lymphocytes and
endogenous brain interleukin-10 signaling.Neuropsychopharmacology (2018).
doi: 10.1038/s41386-018-0154-1
37. Duivis HE, Vogelzangs N, Kupper N, de Jonge P, Penninx BW.
Differential association of somatic and cognitive symptoms of depression
and anxiety with inflammation: findings from the Netherlands study
of depression and anxiety (NESDA). Psychoneuroendocrinology (2013)
38:1573–85. doi: 10.1016/j.psyneuen.2013.01.002
38. Black C, Miller BJ. Meta-Analysis of cytokines and chemokines in suicidality:
distinguishing suicidal versus nonsuicidal patients. Biol Psychiatry (2015)
78:28–37. doi: 10.1016/j.biopsych.2014.10.014
39. Eller T, Aluoja A, Maron E, Vasar V. Soluble interleukin-2 receptor and
tumor necrosis factor levels in depressed patients in Estonia.Medicina (2009)
45:971–7. doi: 10.3390/medicina45120124
40. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al.
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-
blind placebo-controlled randomised phase III trial. Lancet (2006) 367:29–35
doi: 10.1016/S0140-6736(05)67763-X
41. Krogh J, Benros ME, Jørgensen MB, Vesterager L, Elfving B, Nordentoft
M. The association between depressive symptoms, cognitive function, and
inflammation in major depression. Brain Behav Immun. (2014) 35:70–6.
doi: 10.1016/j.bbi.2013.08.014
42. Goodwin RD, Cox BJ, Clara I. Neuroticism and physical disorders among
adults in the community: results from the National Comorbidity Survey.
J Behav Med. (2006) 29:229–38. doi: 10.1007/s10865-006-9048-5
43. Sutin AR, Ferrucci L, Zonderman AB, Terracciano A. Personality and
obesity across the adult life span. J Pers Soc Psychol. (2011) 101:579–92.
doi: 10.1037/a0024286
44. Terracciano A, Costa PTJr. Smoking and the five-factor model of personality.
Addiction (2004) 99:472–81. doi: 10.1111/j.1360-0443.2004.00687.x
45. Foster JA, MacQueen G. Neurobiological factors linking personality
traits and major depression. Can J Psychiatry (2008) 53:6–13.
doi: 10.1177/070674370805300103
46. Barlow DH, Ellard KK, Sauer-Zavala S, Bullis JR, Carl JR. The
origins of neuroticism. Perspect Psychol Sci. (2014) 9:481–96.
doi: 10.1177/1745691614544528
47. Krügel U, Fischer J, Radicke S, Sack U, Himmerich H. Antidepressant effects
of TNF-α blockade in an animal model of depression. J Psychiatr Res. (2013)
47:611–6.
48. Besedovsky HO, del Rey A, Klusman I, Furukawa H, Monge Arditi
G, Kabiersch A. Cytokines as modulators of the hypothalamus-
pituitary-adrenal axis. J. Steroid. Biochem. Mol. Biol. (1991) 40:613–8.
doi: 10.1016/0960-0760(91)90284-C
49. van Velzen LS, Schmaal L, Milaneschi Y, van Tol MJ, van der Wee NJ,
Veltman DJ, et al. Immunometabolic dysregulation is associated with reduced
cortical thickness of the anterior cingulate cortex. Brain Behav Immun. (2017)
60:361–8. doi: 10.1016/j.bbi.2016.10.019
50. Wardenaar KJ, Conradi HJ, Bos EH, de Jonge P. Personality modulates
the efficacy of treatment in patients with major depressive disorder. J Clin
Psychiatry (2014) 75:e916–23. doi: 10.4088/JCP.13m08855
51. Bukh JD, Andersen PK, Kessing LV. Personality and the long-term outcome
of first-episode depression: a prospective 5-year follow-up study. J Clin
Psychiatry (2016) 77:e704–10. doi: 10.4088/JCP.15m09823
52. Spinhoven P, Huijbers MJ, Ormel J, Speckens AEM. Improvement of
mindfulness skills during mindfulness-based cognitive therapy predicts long-
term reductions of neuroticism in persons with recurrent depression in
remission. J Affect Disord. (2017) 213:112–7. doi: 10.1016/j.jad.2017.02.011
53. Lopresti AL. Cognitive behaviour therapy and inflammation: a systematic
review of its relationship and the potential implications for the
treatment of depression. Aust N Z J Psychiatry (2017) 51:565–82.
doi: 10.1177/0004867417701996
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Schmidt, Sander, Minkwitz, Mergl, Dalton, Holdt, Teupser,
Hegerl and Himmerich. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Psychiatry | www.frontiersin.org 8 November 2018 | Volume 9 | Article 609
